Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Did Smith & Nephew PLC LSE:SN. Rise 0.24% Amid a steadier tone across London-listed medical technology shares?

Smith & Nephew PLC — LSE:SN. closed 0.24% higher on21 September 2026, with the shares at 1,030.00p after a gain of 2.50p on the day.

Ishan Mudgal | 21 September 2026

Why Did AstraZeneca PLC LSE:AZN Rise 0.05% Amid a steadier tone across London-listed pharmaceutical shares?

AstraZeneca PLC — LSE:AZN closed 0.05% higher on21 September 2026, with the shares at 12,506.00p after a gain of 6.00p on the day.

Ishan Mudgal | 21 September 2026

Why Did ConvaTec Group PLC LSE:CTEC Rise 0.09% Amid a steadier tone across London-listed medical technology shares?

ConvaTec Group PLC — LSE:CTEC closed 0.09% higher on21 September 2026, with the shares at 214.20p after a gain of 0.20p on the day.

Ishan Mudgal | 21 September 2026

Why Did GSK PLC LSE:GSK Rise 0.35% Amid renewed investor attention on London-listed pharmaceutical shares?

GSK PLC — LSE:GSK closed 0.35% higher on21 September 2026, with the shares at 1,884.00p after a gain of 6.50p on the day.

Ishan Mudgal | 21 September 2026

Why Did Haleon PLC LSE:HLN Rise 0.18% Amid renewed investor attention on London-listed consumer health shares?

Haleon PLC — LSE:HLN closed 0.18% higher on21 September 2026, with the shares at 341.30p after a gain of 0.60p on the day.

Ishan Mudgal | 21 September 2026

What Could ePharmacy Consolidation Mean for FTSE AIM All-Share Stock Vulcan Two Group (LSE:VUL)?

The defining event was the reverse takeover completed on 19 March 2026, through which Vulcan Two acquired CloudRx, Hyperdrug and Webmed, funded by a £40m institutional placing, according to reporting. The company also signed aLeasefor a new distribution centre to support its operations. These …

Ankur Sharma | 21 September 2026

Could Coiled Therapeutics LSE:COIL Extend Its 6.25% Rise as AO-252 Clinical Catalysts Approach?

Coiled Therapeutics LSE:COIL has gained6.25% on 21 September 2026, bringing the clinical-stage oncology company back into focus as investors monitor progress toward important AO-252 clinical milestones.

Ankur Sharma | 21 September 2026

What Is Driving Fusion Antibodies LSE:FAB Higher as Its Antibody Discovery Business Moves Towards Profitability?

Fusion Antibodies LSE:FAB is attracting attention after gaining4.55% on 21 September 2026, according to the market-mover data provided.

Ankur Sharma | 21 September 2026

Why Is ImmuPharma LSE:IMM Rising 17.31% as P140 Patent and Drug Development Progress Gains Attention?

ImmuPharma LSE:IMM is attracting renewed market attention after the shares were shown rising17.31% on 21 September 2026.

Ankur Sharma | 21 September 2026

Could RUA Life Sciences LSE:RUA Extend Its 6.30% Rally as Medical Device Growth Accelerates?

RUA Life Sciences LSE:RUA is attracting attention after rising6.30% on 21 September 2026. The move comes against a backdrop of improving financial performance and continued development of the company's medical-device businesses.

Ankur Sharma | 21 September 2026
Support

Hi! How can we help you today?

Loading…